Cargando…
A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
This study assessed long-term immunogenicity and safety following 3 doses of AS04-adjuvanted human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) vaccine in females 10–14 years old. Girls included in the immunogenicity subset in the primary controlled, observer-blinded, randomized study (NC...
Autores principales: | Schwarz, Tino F., Huang, Li-Min, Valencia, Alejandra, Panzer, Falko, Chiu, Cheng-Hsun, Decreux, Annabelle, Poncelet, Sylviane, Karkada, Naveen, Folschweiller, Nicolas, Lin, Lan, Dubin, Gary, Struyf, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746471/ https://www.ncbi.nlm.nih.gov/pubmed/31268383 http://dx.doi.org/10.1080/21645515.2019.1625644 |
Ejemplares similares
-
Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017) -
Long‐term persistence of immune response to the AS04‐adjuvanted HPV‐16/18 vaccine in Chinese girls aged 9‐17 years: Results from an 8‐9‐year follow‐up phase III open‐label study
por: Hu, Yuemei, et al.
Publicado: (2020) -
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
por: Folschweiller, Nicolas, et al.
Publicado: (2019) -
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020) -
Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial
por: Huang, Li-Min, et al.
Publicado: (2017)